(Q37791398)

23 August 2017

title

Bladder cancer: a review of non-muscle invasive disease (English)

1 reference

23 August 2017

1 reference

1 reference

Wade J Sexton

1

1 reference

23 August 2017

Lucas R Wiegand

2

1 reference

23 August 2017

José J Correa

3

1 reference

23 August 2017

Christos Politis

4

1 reference

23 August 2017

Shohreh Iravani Dickinson

5

1 reference

23 August 2017

Loveleen C Kang

6

1 reference

23 August 2017

publication date

1 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

17

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

256-268

1 reference

Trends in the leading causes of death in the United States, 1970-2002.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Risk of bladder cancer by source and type of tobacco exposure: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Epidemiology of urinary bladder cancer: from tumor development to patient's death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

The accuracy of urinary cytology in daily practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Urine markers for bladder cancer surveillance: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Molecular markers in bladder cancer: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Percutaneous peritoneal drainage for intraperitoneal bladder perforations during transurethral resection of bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Clonal origin of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Management of stage T1 tumors of the bladder: International Consensus Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Treatment options for BCG failures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Superficial bladder cancer: the role of interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Intravesical bacillus Calmette-Guèrin therapy: experience with a reduced dwell-time in patients with pronounced side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

Interference of modern antibacterials with bacillus Calmette-Guerin viability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700406

10.1177/107327481001700406

21 January 2018

Identifiers

DOI

0 references

1 reference